Prediction of PARP inhibitor response and resistance utilizing a CTC phenotypic classifer in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results from the NCI 9012 trial

被引：0
|
作者：
Feng, F. Y. [1 ]
Daignault-Newton, S. [2 ]
Jendrisak, A. [3 ]
Wang, Y. [3 ]
Greene, S. [3 ]
Rodriguez, A. [3 ]
Lee, J. [3 ]
Dugan, L. [3 ]
Siddiqui, J. [4 ]
Louw, J. [3 ]
Johnson, C. [3 ]
Twardowski, P. [5 ]
Albany, C. [6 ]
Stein, M. [7 ]
Stadler, W. M. [8 ]
Kunju, L. [4 ]
Chinnaiyan, A. M. [4 ]
Landers, M. [3 ]
Dittamore, R. [3 ]
Hussain, M. [9 ]
机构：
[1] UCSF Helen Diller Family Comprehens Canc Ctr, Radiat Oncol, San Francisco, CA USA
[2] Univ Michigan, Biostat, Ann Arbor, MI 48109 USA
[3] Epic Sci Inc, Translat Res, San Diego, CA USA
[4] Univ Michigan, Michigan Ctr Translat Pathol, Ann Arbor, MI 48109 USA
[5] City Hope Natl Med Ctr, Med Oncol & Expt Therapeut, Duarte, CA USA
[6] Indiana Univ, Simon Canc Ctr, Med Oncol, Indianapolis, IN 46204 USA
[7] Canc Inst New Jersey, Div Med Oncol, New Brunswick, NJ USA
[8] Univ Chicago, Med Ctr, Med Oncol, Chicago, IL 60637 USA
[9] Univ Michigan, Med Oncol, Ann Arbor, MI 48109 USA
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw372.14
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
730PD
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012
    Hussain, Maha
    Daignault-Newton, Stephanie
    Twardowski, Przemyslaw W.
    Albany, Costantine
    Stein, Mark N.
    Kunju, Lakshmi P.
    Siddiqui, Javed
    Wu, Yi-Mi
    Robinson, Dan
    Lonigro, Robert J.
    Cao, Xuhong
    Tomlins, Scott A.
    Mehra, Rohit
    Cooney, Kathleen A.
    Montgomery, Bruce
    Antonarakis, Emmanuel S.
    Shevrin, Daniel H.
    Corn, Paul G.
    Whang, Young E.
    Smith, David C.
    Caram, Megan V.
    Knudsen, Karen E.
    Stadler, Walter M.
    Feng, Felix Y.
    Chinnaiyan, Arul M.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (10) : 991 - +
  • [2] CTC counts as a biomarker of prognosis and response in metastatic castration-resistant prostate cancer (mCRPC) from the CARD trial.
    De Bono, Johann S.
    Pantel, Klaus
    Efstathiou, Eleni
    Sternberg, Cora N.
    Castellano, Daniel
    Fizazi, Karim
    Tombal, Bertrand
    Wulfing, Christian
    Schonhoft, Joseph D.
    Gill, Audrey
    Chu, Lincy
    Wenstrup, Rick
    Ozatilgan, Ayse
    Geffriaud-Ricouard, Christine
    Mace, Sandrine
    De Wit, Ronald
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [3] Genetic polymorphisms to predict progression-free survival in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving abiraterone therapy: Results from the NCI 9012 trial.
    Albany, Costantine
    Daignault-Newton, Stephanie
    Skaar, Todd C.
    Ipe, Joseph
    Siddiqui, Javed
    Twardowski, Przemyslaw
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [4] Statin use and outcome in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated in the TROPIC trial
    Lorente, D.
    De Velasco Oria, G. A.
    Carles, J.
    Gillessen, S.
    Fizazi, K.
    Joshua, A.
    Eisenberger, M.
    Sartor, O.
    de Bono, J. S.
    ANNALS OF ONCOLOGY, 2018, 29
  • [5] The TRITON clinical trial programme: Evaluation of the PARP inhibitor rucaparib in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD)
    Chowdhury, S.
    Abida, W.
    Arranz Arija, J.
    Daugaard, G.
    Fizazi, K.
    Gez, E.
    Heidenreich, A.
    Joly Lobbedez, F.
    McDermott, R.
    Merseburger, A. S.
    Piulats Rodriguez, J. M.
    Sautois, B.
    Sridhar, S.
    Sternberg, C. N.
    Watkins, S.
    Simmons, A.
    Shetty, S.
    Golsorkhi, A.
    Ryan, C. J.
    Scher, H.
    ANNALS OF ONCOLOGY, 2017, 28
  • [6] ENCORE: A phase 2 trial of enfortumab vedotin (EV) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
    Swami, Umang
    Faust, Caitlin
    Leonhart, Samuel
    Haaland, Benjamin
    Jones, Kristen
    Li, Haoran
    Sahu, Kamal Kant Kant
    Thomas, Vinay Mathew
    Phunrab, Tenzin Kunsang
    Batten, Julia
    Maxwell, Lindsay
    Lloyd, Jennifer
    Kohli, Manish
    Gupta, Sumati
    Thorne, Kelli
    Maughan, Benjamin L.
    Agarwal, Neeraj
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [7] DNA Repair Gene Alterations and PARP Inhibitor Response in Patients With Metastatic Castration-Resistant Prostate Cancer
    Lu, Eric
    Thomas, George V.
    Chen, Yiyi
    Wyatt, Alexander W.
    Lloyd, Paul
    Youngren, Jack
    Quigley, David
    Bergan, Raymond
    Bailey, Shawna
    Beer, Tomasz M.
    Feng, Felix Y.
    Small, Eric J.
    Alumkal, Joshi J.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2018, 16 (08): : 933 - 937
  • [8] A phase 1 study of AMG 509 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Danila, Daniel Costin
    Waterhouse, David Michael
    Appleman, Leonard Joseph
    Pook, David William
    Matsubara, Nobuaki
    Dorff, Tanya B.
    Lee, Jae-Lyun
    Armstrong, Andrew J.
    Kim, Miso
    Horvath, Lisa
    Sumey, Christopher Joseph
    Cooner, Freda
    Salvati, Mark
    Stieglmaier, Julia
    Kelly, William Kevin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [9] Characterizing longitudinal molecular changes in ctDNA in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
    Tran, Eli
    Jani, Chinmay
    Zhang, Nicole
    Tsai, Jill
    Pan, Elizabeth
    Panian, Justine
    McKay, Rana R.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 205 - 205
  • [10] Treatment (Rx) patterns and attrition rates in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
    Gebrael, Georges
    Jo, Yeonjung
    Hage Chehade, Chadi
    Ozay, Zeynep Irem
    Sayegh, Nicolas
    Ostrowski, Micah
    Campbell, Patrick
    Anderson, Ethan
    Nordblad, Blake
    Galarza Fortuna, Gliceida M.
    Mathew Thomas, Vinay
    Riaz, Irbaz Bin
    Graf, Ryon P.
    Guha, Avirup
    Maughan, Benjamin L.
    Roy, Soumyajit
    Antonarakis, Emmanuel S.
    Agarwal, Neeraj
    Swami, Umang
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
12345